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Ovarian carcinoma immunoreactive antigen-like protein 2 (OCIAD2) is a protein with unknown function. Frequently methylated
or downregulated, OCIAD2 has been observed in kinds of tumors, and TGF𝛽 signaling has been proved to induce the expression of
OCIAD2. However, current pathway analysis tools do not cover the genes without reported interactions like OCIAD2 and alsomiss
some significant genes with relatively lower expression. To investigate potential biological milieu of OCIAD2, especially in cancer
microenvironment, a nova approach pbMOOwas created to find the potential pathways fromTGF𝛽 toOCIAD2by searching on the
pathway bridge, which consisted of cancer enriched looping patterns from the complicated entire protein interactions network.The
pbMOO approach was further applied to study the modulator of ligand TGF𝛽1, receptor TGF𝛽R1, intermediate transfer proteins,
transcription factor, and signature OCIAD2. Verified by literature and public database, the pathway TGF𝛽1- TGF𝛽R1- SMAD2/3-
SMAD4/AR-OCIAD2 was detected, which concealed the androgen receptor (AR) which was the possible transcription factor of
OCIAD2 in TGF𝛽 signal, and it well explained themechanism of TGF𝛽 induced OCIAD2 expression in cancer microenvironment,
therefore providing an important clue for the future functional analysis of OCIAD2 in tumor pathogenesis.
1. Background
Tumor microenvironment has been largely studied as a
dynamic system to define the behaviors of cancer.This system
is orchestrated by cytokines, growth factors, inflammatory
cells, cancer cells, stroma, as well as the extracellular matrix
[1]. Tumor-associated fibroblasts (TAFs) are major elements
of tumor stroma and have been shown to play an impor-
tant role in tumor growth and progression. Epithelial-to-
mesenchymal transition (EMT) is a major source of TAFs.
In tissue fibrosis, it is well-established that epithelial cells
contribute to the accumulation of fibroblasts by undergoing
EMT in response to stimuli from the microenvironment
[2]. TGF𝛽 remains among the key factors responsible for
the recruitment of Tumor Associated Fibroblasts (TAFs) and
induction of EMT. TAFs, meanwhile, strongly contribute
to the production and activation of TGF𝛽 in the activated
stroma and thereby generate the autocrine feed-forward loop
that is characteristic for persisting fibroblasts activities [3].
However, the exact regulation between TGF𝛽 signals and
TAFs in tumor microenvironment is yet to be completely
understood.
OCIAD2 was originally immunoscreened from ascites
of a patient with ovarian cancer and was found to be
an immunoreactive antigen [4]. However, the function of
OCIAD2 protein, involved pathways, and molecular mech-
anisms has never been reported. Based on our preliminary
data analysis, we hypothesized that human OCIAD2 repre-
sents a potential tumor suppressor gene in some tumor types
and its dysregulation is involved in TGF𝛽 regulated signaling
in tumor microenvironment for the following reasons: (1)
high-throughput profiling data and public database analyses
showed that OCIAD2 is frequently methylated and/or down-
regulated in some kinds of cancers [5–7]; (2) GEO database
revealed that the expressions of OCIAD2 are induced by
TGF𝛽 signal in pancreatic (GSE23952), lung adenocarcinoma
(GSE17708), and ovarian cancer cells (GSE6653); (3) more-
over, a computational analysis with TCGA database revealed
that methylation site of OCIAD2 is top-ranked signature in
ovarian Metastasis-Associated Fibroblasts (MAFs) [8]. This
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evidence indicated a potential biological milieu of OCIAD2.
We hereby speculate that downregulatedOCIAD2 expression
in tumor microenvironment facilitates deregulated TGF𝛽
signaling. As a consequence of these changes, tumor cells
escape immunosurveillance and exaggerate tumor progres-
sion and metastatic spread.
To predict molecular network of OCIAD2 in TGF𝛽
regulated tumor microenvironment, a nova pathway analysis
approach with bioinformatics methods has been developed.
Current signal analysis methods typically have three steps:
build literature based preliminary signaling pathways model;
generate gene expression experimental data; detect the short-
est path as the specific signal and verify biological meaning.
Pathways consisting of highest differentially expressed genes
and reported interactions would be shown as the results
in this kind of pathway study methods. However, not all
the targets or receptors of ligands are with top expression
changes; that is, TGF𝛽 regulates numerous other growth
factors positively and negatively, some of which are not the
most obviously changed ones but still give response to the
stimulation of TGF𝛽. Moreover, new genes with seldom
previous reports, such as OCIAD2, cannot be included in
any pathways because of the lack of known interactions with
other proteins. To study the mechanism of OCIAD2 changes
induced by TGF𝛽 stimulation in cancer cell lines, a new
approach to inferring the signaling paths based on the path-
way bridges between the stimulant TGF𝛽 and its target gene
OCIAD2 using the multiobjective optimization approach,
named pbMOO, was developed. Pathway Bridge was defined
as a subset of protein interactions network that consisted
of clustering loop motifs with extremely high frequency
occurring in cancer related processes than by chance. All
four-vertex motifs, among which the triangle and rectangle
were shown with significantly higher occurrences than ran-
domized ones, were detected from a network generated from
HPRD database with 12794 proteins and 39031 interactions.
Rather than traversing the entire protein interaction network
with enormous nodes and edges, all the loop motifs were
clustered as a “Pathway Bridge” between TGF𝛽 signaling
pathway and cancer signaling pathway. Relatively, the time
saving approach returned to highly reliable protein paths
only by searching connecting nodes on the bridge. Moreover,
motifs on the bridge were concentrated on cancer related
processes, which guaranteed that the nodes chosen for the
path are specified for cancer microenvironment. Then, the
cost of a protein path was defined by gathering up the cost of
each edge, which is the P value sum of two interacted protein
nodes. According to the property of 𝑃 value, the path cost is
the probability of obtaining a pathwhose cost is nomore than
the one that was actually observed. Hence, the reliability of a
predicted pathway can be represented by its cost.
177 transcription factors of Homo sapiens were analyzed
from Transcriptional Regulatory Element Database [9], and
androgen receptor (AR) was discovered as the most credible
transcription factor of OCIAD2. Applied the approach on
GSE42357 andGDS3634 expression data fromNCBI, and the
paths with the lowest cost were picked out as the responsible
possiblemolecularmechanisms betweenTGF𝛽 andOCIAD2
in hepatocellular carcinoma (HCC) samples and prostate
cancer cell lines. After verifying the biological meaning of
the low-cost paths, the signal TGF𝛽1- TGF𝛽R1- SMAD2/3-
SMAD4- AR-OCIAD2 was discovered and explained TGF𝛽’s
stimulation on OCIAD2 expression in cancer.
2. Methods
In order to see how the signature gene is enrolled in the ligand
stimulation signal, a pathway bridge based multiobjective
optimization approach (pbMOO) was designed and summa-
rized, as shown in Figure 1. Three kinds of data were chosen
as the initial input data: protein interactions (Figure 1(a))
fromHPRD [10] were applied for building the entire protein-
protein interactions (PPI) network; signaling pathways (Fig-
ure 1(b)) from both KEGG [11] and IPA [12] were selected
as the background pathway library based on which the
pathway bridges were constructed; groups of microarray
data (Figure 1(c)) were used for assigning the path cost
in the optimization problem and presenting the correlation
between genes. Calculated by FANMOD [13], loop motifs
(Figure 1(a1)), which were the higher frequency occurring
subnetworks out of the entire PPI network, were shown to
be enriched in cancer and related pathways. Searching on
the pathway bridge (Figure 1(b2)), which was defined as a
set of loop motif clusters (Figure 1(a2)) connecting ligand
and signature genes, a multiobjective optimization problem
was solved by finding the pathways with the lowest path cost
that was assigned by gene expression 𝑃 value. When multiple
experimental gene expression data were used, the cost of each
path was then defined as the summation of average 𝑃 value
of connected genes in the optimization problem. Then the
modular study (Figure 1(c1)) was applied on the calculated
results of the optimization problem. Finally, the integrated
signals, which began with ligand and its receptor, passing
through transduction proteins and targeting transcription
factor and finally the signature, were output as the most
reliable predicted pathways (Figure 1(c2)) explaining how the
ligand changes affected the signature.
2.1. Cell Lines and Drug Treatment. Hep-3B and Du-145 were
obtained from American Type Culture Collection. All cell
lines were cultured in DMEM with 10% fetal bovine serum
(FBS) and antibiotics. TGF𝛽1 (R&D Systems, Minneapolis,
MN) were applied at concentrations of 5 ng/mL. TGF𝛽R
inhibitor LY2109761 were purchased from Selleck Chemicals
LLC (Houston, TX), using 2𝜇M. For the drug treatment,
human liver and prostate cancer cell lines, Hep-3B and Du-
145 were treated with 5 ng/mL TGF𝛽1, 2 𝜇M LY2109761, and
combination for 24 hours in serum free media, and OCIAD2
mRNA levels were determined by quantitative real-time RT-
PCR analysis.
2.2. RNA Extraction and Quantitative Real-Time PCR. Total
RNAs were isolated from tumor cells using TRIZOL reagent
(Life Technologies, USA) following the manufacturer’s rec-
ommendations. RNA concentration and purity were deter-
mined by measuring absorbance at 260 and 280 nm with a
NanoDropTM 1000 Spectrophotometer (Thermo Scientific,
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Figure 1
USA). cDNA synthesis was performed with Superscript III
reverse transcriptase kit (Life Technologies, USA). Quanti-
tative real-time reverse-transcription polymerase chain reac-
tion (RT-PCR) was performed using an Applied Biosys-
tems 7300 Sequence detection system (Applied Biosys-
tems, Life Technologies, USA). The primer sets of OCIAD2
are described below: 5󸀠-TGCGAGAATGTCAGGAAGAA-3󸀠
and 5󸀠-AAATCCCAAGAGACCAGCAA-3󸀠.
2.3. Motif Detection of Protein-Protein Interaction Network.
“Network Motifs” [14] are interconnected patterns (sub-
graphs) with significantly higher occurring in complicated
networks than in randomized ones. In biological networks,
almost all of the four vertex motifs were combinations of
smaller motifs [15], and loop-structural motifs have been
proved to be enriched in a protein-protein interaction (PPI)
network generated from PPI database, that is, HPRD. As a
literature-collected public database, HPRD has 12794 pro-
teins and 39031 pairs of interactions for 9605 of them. The
sufficient data capacity helps a lot on unclear reciprocities
prediction.
In this paper, the outstanding tool Fast Network Motif
Detection (FANMOD) [13] was applied to census four-
vertex subgraphs in undirected PPI network by using the
Randomized Enumeration (RAND-ESU) algorithm.
Motifs detection results from PPI network were shown
as an example in Figure 2 and detailed in Supplemen-
tary 1.1 in Supplementary Material available online at
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Figure 2
http://dx.doi.org/10.1155/2014/351095. Motifs ID lied in col-
umn one and adjacency matrix was presented in the second
column; Frequency was the probability of each motif in orig-
inal PPI network, and Mean-Frequency was of the motif that
occurred in random networks; the standard deviation from
the mean frequency was listed in the fifth column; Z-score
meant the value of the difference of two frequencies divided
by the standard deviation; and P value was the difference of
motif numbers between random networks and original one
then divided by the total number of random networks. ID
8598 in Figure 2 had relatively higher occurring frequency in
random networks than the original one, and thus its 𝑍-Score
was negative and P value was large, which indicated that the
chain-looked structure was really normal among the entire
PPI network; on the contrary, ID 31710 was more special
in the original network structure than randomly showing
that the combination of triangle and square subnetwork was
enriched among PPI network. Similarly, motifs ID 4382,
recurringmuchmore often than random chosen subnetwork,
were with negative 𝑍-Score and large P value; ID 13278,
ID 4958, and ID 27030 motif structures were also enriched
from randomized network and obtain positive 𝑍-Score and
relatively smaller P value.The whole results were listed in the
supplementary.The outcome suggests loop-structuralmotifs,
that is, shapes like triangle, spoon, and square, which are
special patterns with high occurrences in protein interactions
network.
20 signaling pathways derived from KEGG [11] were
analyzed for motifs distribution. Results in Figure 3 showed
that proteins on looping motifs are mainly from cancer
and correlated signal pathways, in other words, motifs with
loop structure are enriched in 14 types of carcinomatosis
and related signaling pathways, such as cell cycle signaling
pathway and immune system signaling pathways.
2.4. Motifs Clustering and Enrichment in Cancer Related
Signaling Pathways. Loop-shaped motifs with no more than
four vertices have the only two specific possibilities—triangle
and square. Motifs Cluster (MC) is defined as converged
cyclic motifs that share at least one protein. The common
protein is called Center Point (CP), which is the identifier
for distinguishing differentmotifs clusters.The toymodelwas
showed in Figure 4.
Since looping motifs were proved to be occurring much
more often in cancer and related signaling pathways, they
can be treated as a bridge to link up cancer and its kinship
pathways, which would provide a characteristic group of can-
didate protein interactions for future unclear links forecast.
Let 𝑃
1
be a chosen cancer signaling pathway, and let
𝑃
2
be a cancer-related signaling pathway. {MC𝑃1𝑃2
1
,MC𝑃1𝑃2
2
,
. . . ,MC𝑃1𝑃2
𝑛
} are the total 𝑛motif clusters between 𝑃
1
and 𝑃
2
,
and thus |MC𝑃1𝑃2 | = 𝑛 by virtue of the number of identifiers
|CP𝑃1𝑃2 | = 𝑛, where | ⋅ | denotes the number of elements
in a set. In order to evaluate the enrichment of MCs lying
between 𝑃
1
and 𝑃
2
, 𝑃 value was introduced as the probability
of obtaining a larger number of MCs for a pair of randomly
chosen protein sets, keeping the same sizes with𝑃
1
and𝑃
2
and
the capacity of intersection, than for 𝑃
1
and 𝑃
2
. Consider the
following:
𝑝 = prob {𝑛󸀠 > 𝑛 | 𝑛󸀠 = 󵄨󵄨󵄨󵄨󵄨MC
𝑆
1
𝑆
2
󵄨󵄨󵄨󵄨󵄨 , 𝑛 =
󵄨󵄨󵄨󵄨󵄨MC
𝑃
1
𝑃
2
󵄨󵄨󵄨󵄨󵄨} , (1)
where 𝑆
1
and 𝑆
2
are random protein sets picked out from
entire proteins of HPRD database with the same size as 𝑃
1
and 𝑃
2
; that is, |𝑆
1
| = |𝑃
1
| and |𝑆
2
| = |𝑃
2
|, and satisfy
|𝑆
1
⋂𝑆
2
| = |𝑃
1
⋂𝑃
2
|. Repeating the sampling for 1000 times,
a random distribution 𝑓 for the 1000 numbers of MCs can be
generated. The complementary set of cumulative probability
density function 𝐹(|MC𝑃1𝑃2 |) interprets the chances that a
stochastic pair of protein sets has quantity of MCs which are
being the bridges between them rather than the two chosen
pathways, which is indeed motif clusters’ 𝑃 value. Consider
the following:
𝑝 = 𝐹󸀠 (
󵄨󵄨󵄨󵄨󵄨MC
𝑃
1
𝑃
2
󵄨󵄨󵄨󵄨󵄨) = 1 − 𝐹 (
󵄨󵄨󵄨󵄨󵄨MC
𝑃
1
𝑃
2
󵄨󵄨󵄨󵄨󵄨) . (2)
MCs connecting 𝑃
1
and 𝑃
2
are enriched if the 𝑃 value is tiny,
indicating that the bridging MCs linking up two protein sets
are the main substructure of cancer signaling path 𝑃
1
and
cancer enrolled signaling path 𝑃
2
. Comparing with searching
the enormous and complex integrated PPI network, the
enriched MCs bridge efficiently limits and specializes the
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Figure 3
traversing range for forecasting uncertain protein paths,
which increases the calculation speed thoroughly.
MCs’ 𝑃 value for combinations of different types and
subtypes of carcinomatosis and involved signaling pathways
were calculated and exampled in Figure 5. MCs bridges that
have 𝑃 value less than 0.01 were chosen to be the candidate
subnetwork, from which ill-defined protein pathways would
be selected.
2.5. Ill-Defined Protein Pathways Prediction. If changing
condition of a protein A results in the upregulated or
downregulated protein B, while A and B have neither direct
interaction with each other nor indirect upstream and down-
stream relationship on any authentic signaling pathway, the
underlying protein pathways for them could be detected
on those MCs enriched pathway bridges. An optimization
model, which is described as follows,was employed to acquire
high-confidence potential protein pathways:
𝑓 (𝑥) = argmin
⃗𝑥∈{MC𝑃1𝑃2
1
,MC𝑃1𝑃2
2
,...,MC𝑃1𝑃2𝑛 }
𝑁
∑
𝑖=1
𝑥
𝑖
⋅ DES
𝑖
+ 𝜆
𝑁
∑
𝑖=1
𝑥
𝑖
,
s.t.
{{{{
{{{{
{
2 ≤
𝑁
∑
𝑖=1
𝑥
𝑖
≤ 7,
𝑖 = 1, 2, . . . , 𝑁,
𝜆 ∈ |R| ,
(3)
where 𝑁 is the total number of proteins pertaining to MCs
bridge for the selected pair 𝑃
1
and 𝑃
2
. ?⃗? = {𝑥
1
, 𝑥
2
, . . . , 𝑥
𝑁
} is
protein path vector implying which element was contributed
to the path—if protein 𝑖 was taken count into the lurking
protein path, then 𝑥
𝑖
= 1; otherwise, 𝑥
𝑖
= 0. Differential
expression score (DES) was defined by each gene’s 𝑃 value
from Student’s 𝑡-test of gene expression experiment data in
two conditions. The larger the 𝑃 value, the larger the DES,
and the less reliable the data. Thus, minimizing the first part
of the objective function ∑𝑁
𝑖=1
𝑥
𝑖
⋅ DES
𝑖
could ensure the
maximization of the reliability of the predicted protein paths.
The length of protein pathway; that is, ∑𝑁
𝑖=1
𝑥
𝑖
, is an integer
in the range of [2, 7], which was decided by the fact that
MCs were composed of looping structures up to 4 vertices.
At this point, the latter part of the objective function took the
responsibility of controlling the length of analyzed protein
pathway with the aid of distinct settings of nonnegative
parameter 𝜆. |R| is the absolute value of real number. Large
𝜆 was made for limited proteins and short connections, and
optimization result was free to rope in proteins when 𝜆 = 0.
The optimization functionwas solved by the shortest path
package in R, where Dijkstra’s algorithm was employed and
the length controlling parameter 𝜆 was set as zero to gain
all the possible predictions. The solution of the optimization
function was the optimal protein path vector ?⃗? of𝑁 elements
𝑥
𝑖
, representing protein 𝑖 was in the lowest-cost path or not.
2.6. Interacted Pairs Inference for Protein without PPI. For
those proteins that have no canonical protein interaction
supported, gene expression data was conduced to providing
indistinct mutual effects and pointing out candidate proteins
with which the separated proteins were closely bound up by
the correlation between the pairs of genes.
2.7. Multiple Microarray Data Based Differential Expression
Score. As a matter of fact, the P value of experimental
gene expression data may vary a lot by different experiment
designs and operators, and a good inferred protein path is the
one which gets rid of the destabilizing factors. Thus, multiple
microarray data sets were employed here for error deduction.
3. Results and Discussion
3.1. Dysregulation of OCIAD2 in Different Cancers and Its
Induction by TGF𝛽 in HCC and PC Cells. To determine the
6 BioMed Research International
(a) (b) (c)
Figure 4
OCIAD2 expression, different available microarray studies
were analyzed by the Oncomine database and GEO gene
microarray data analysis tools. A significant downregulation
of OCIAD2 mRNA expression was found in liver cancer
and gastric stroma carcinoma tissues (𝑃 < 0.001 in both
cases) (Figure 6; Left) based on Oncomine database analysis.
The result indicated that OCIAD2 expression is in metastatic
prostate tissues, but not in primary tumor tissues, which is
clearly lower than normal prostate gland (𝑃 = 0.009) (Fig-
ure 6; Right; GSE6919). Frequently downregulated OCIAD2
expressions are also observed in CLL and malignant pleural
mesothelioma [5, 6]. In glioblastoma, OCIAD2 expression is
being silenced via DNA methylation mechanism [7]. With
the suggestion of the fact that OCIAD2 was substantially
unregulated in TGF𝛽1 treated pancreatic (GDS4106), lung
(GSE17708), and ovarian (GSE6653) cancer cells, we have
tested the possibility of OCIAD2 expression inducted by
TGF𝛽 in HCC and PC cells. Human HCC and PC cell lines,
Hep-3B and Du-145, were treated with 5 ng/mL TGF𝛽1, 2𝜇M
LY2109761, and combination for 24 h in serum free media,
and OCIAD2 mRNA levels were determined by quantitative
real-time RT-PCR analysis. OCIAD2 mRNA has increased
2.5- and 4.6-fold in Hep-3B and Du-145 cells by TGF𝛽1
treatment, respectively.This induction was totally suppressed
by TGF𝛽1 receptor inhibitor LY2109761 (Figure 6(b)).
3.2. Potential Protein Pathway Prediction. Remarkable gene
array profiles from GEO database indicated the expression of
OCIAD2 in several kinds of cancer; that is, GDS3634 showed
that OCIAD2 was obviously unregulated in prostate cancer
cell line transfected with 20 nMmiRNA Presursor Molecules
miR-205. MiR-205 is selectively downregulated in metastatic
breast and prostate cancer and suppresses metastatic spread
of a human breast cancer xenograft in nude mice. In addition
to its function in the regulation of EMT, the loss of miR-205
in prostate cancer also reduced some tumor suppressor genes’
expression.
Mesenchymal stem cells (MSC), like other bone marrow-
resident cells, have the capacity to differentiate into fibroblast-
like cells that have been variably referred to asmyofibroblasts,
tumor-associated fibroblasts (TAF), fibrocytes, or pericytes
within the tumormicroenvironment [16].Therefore, pbMOO
approach was applied on both prostate cancer cell line
GDS3634 and liver cancer associated mesenchymal stem
cells GSE42357 gene expression data to study the possible
molecular path involved in OCIAD2 by TGF𝛽 stimulation.
3.2.1. Pathways in Prostate Cancer. Based on experimental
data GDS3634, miR-205 expression effect on prostate cancer
cell line, from NCBI public database browser, P value of 8
samples of Student’s 𝑡-test, microarray data was applied as the
link cost for predicted paths. Searched on the pathway bridge
that has been enriched through prostate cancer pathways,
the top 10 out of 88 forecasted paths were picked for further
biological meaning verification (Supplementary Table 1.2).
One reasonable forecast shown in Figure 7 was miR205-
PRKCE- CNA13- CDH1- PTPN14-OCIAD2. High correlated
genes with OCIAD2 were distinguished as dashed lines (red
for positive correlation and green for negative correlation).
PRKCE, as one of the six target genes of miR205, was marked
as the green box. Among the pathway bridge that consisted
of protein nodes (dashed circles) and proteins’ interactions
(green lines), a shortest protein path with least DES cost was
emphasized by red lines.
Suggested by the significant association between TGF𝛽1
and CDH1, pbMOO approach was employed again aiming
at finding out how TGF𝛽 affects OCIAD2 across CDH1
in prostate cancer. Interestingly, “TGF𝛽1 influenced CDH1
across SMADs” was observed after filtering the predicted
protein paths and verified by [17].
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Figure 5: (a) Enriched Motif Clusters between EGFR1 and T cell receptor pathways. (b) Less Enriched Motif Clusters between EGFR1 and
Wnt pathways.
3.2.2. Pathways in Liver Cancer. By the analysis of GSE42357
gene expression data, genes like C5, AG7, SDC2, and FHL2
have been suggested to be the candidates of OCIAD2 by
their tight correlations with it. Significantly, those candidate
genes all play important roles in cancer related processes,
for instant, C5 takes the responsibility in inflammatory and
cell killing processes [18] and FHL2 acts as both tumor-
promoter or tumor-suppressor depending on different types
of cancer [19]. The calculated results of the approach were
pathswith credibility cost, that is, TGF𝛽1- TGF𝛽R1-CLU-C7-
C5-OCIAD2 (cost 0.233181).This pathwaywas fully explained
by the fact that CLU is a modulator of TGF𝛽1 signaling
pathway by regulating Smad2/3 proteins [20] and the well-
known protein interactions CLU-C7 and C7-C5.
3.3. Modular Mechanism Exploration. If a signaling trans-
mission process, from extracellular through cytoplasm to
nucleus, results in upregulation or downregulation of genes
in the cell, then transcription factor (TF) usually plays the
downstream role in this signaling flow. Since OCIAD2 was
differentially expressed in prostate cancer cell line, liver
cancer was associated with mesenchymal stem cells, and
especially in TGF𝛽 treated Panc-1 pancreatic adenocarci-
noma cell line, and the question how is OCIAD2 activated
by TGF𝛽 signaling was solved by studying the probable
transcription factor of OCIAD2, which also acting as the
downstream of TGF𝛽 signal.
Among all the 30981 genes from Transcriptional Reg-
ulatory Element Database [9], 177 transcription factors of
homo sapiens were picked out as background human tran-
scription factors library.. The algorithm to find the possible
transcription factors of OCIAD2 in TGF𝛽 treated signaling
was divided into three main steps: first, pbMOO approach
was employed to calculate the costs of all the shortest paths
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Figure 6: Expression of OCIAD2 and its induction by TGF-𝛽.
between TGF𝛽 and human transcription factors; then the
ones with the least costs and high correlations with OCIAD2
in gene expression data were filtered out and selected as can-
didate transcription factors for OCIAD2; finally, biological
TGF𝛽 induced OCIAD2’s differential expression mechanism
which was concluded with literature verification.
3.3.1. Speculation of Human TF Enrolled in TGF𝛽 Signal.
As a fresh gene with rare reported property, the discovery
of transcription factor in TGF𝛽1 signal is the main issue
in OCIAD2 study. Among those 177 human transcription
factors, the ones with the least pathway cost, which was
defined by the sum of gene expression experimental P value
of proteins on the pathway, are the most credible TFs for
OCIAD2. The start point of the pathway was chosen as
TGF𝛽1, and the end pointwasOCIAD2.All the pathway costs
for those passing through TFs were calculated by applying
pbMOO approach and the top of them were listed in the
Supplementary Table 1.3.
3.3.2. Feasible TF of OCIAD2 in Cancer Cell Line. In this
part, verification of the observation that AR might be the
transcription factor of OCIAD2 in TGF𝛽1 signal, and SMAD
BioMed Research International 9
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Figure 8
groupmight enroll this process, was made in the light of gene
expression data frombothHCC and prostate cancer cell lines.
Due to the fact that GSE42357 gene expression data
was the comparison between liver cancer associated mes-
enchymal stem cells (LC8-MSC) and normal ones (LN8-
MSC) from the same patient, genes like OCIAD2 had only
two experimental values—one for condition LC8-MSC and
one for control LN8-MSC. The sample space was too tiny
for Pearson Correlation calculation. For better results, the
distribution of the fold change of each gene was plotted as
the following Figure 8, and evidently, AR, which had ten
pairs of experiment data in the range [1.09315, 1.74845], highly
differentially expressed in HCC microenvironment. The fold
change value of OCIAD2 in the same array data is −0.377255,
which implied that ARmust have negative effect onOCIAD2,
in the other words, it should be the inhibitor of OCIAD2.
Not like the top obviously expressed genes with fold changes
close to 3.0, the SMAD group showed the relatively lower
differential expression—most of them had slight positive
changes less than 0.1. However, SMAD4 with fold change
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0.06034, SMAD2 0.4908, and SMAD3 0.02102 still survived
as pathway proteins in pbMOO predictions, which were
ignored by other pathway analysis methods.
Analyzing the results (top 30were detailed in Supplemen-
tary Table 1.3), two interesting facts were observed: AR was
shown with the highest frequency as the transcription factor
of OCIAD2 in 17 pathways out of the top 50, while STAT5A
was the second recurrent one that was the transcription
factor of 10 pathways; AR appeared 34 times, and SMAD
group proteins appeared 16 times in the top 50 pathways
with lowest cost, in which other transcription factors had
less occurrences.The observation insinuated that AR was the
most reliable transcription factor of TGF𝛽1 signal induced
OCIAD2, and SMAD group proteins had the closest relation-
ships with this signaling process.
In DU145 prostate cancer cell line with restored miR-
205 expression, unfortunately no data mapping with AR
was found. However, these 8 samples of experimental data
were still powerful to analysis how SMADs enrolled in
OCIAD2 expression. As the figure showed, SMAD4 had
the largest expression value as well as the highest negative
correlation −0.696476 with differential expressed OCIAD2
among SMADs, followed by SMAD2 with correlation value
−0.595238 and SMAD6 −0.571429.
3.3.3. Mechanism of TGF𝛽 Induced OCIAD2’s Expression.
Analyzing the observations comprehensively on modular
study and referring to related literature, the signaling pathway
from TGF𝛽1 targeting OCIAD2 was concluded as shown in
Figure 9: the signaling transmits from TGF𝛽1- TGF𝛽R1- AR-
OCIAD2 in liver cancer mesenchymal stem cell, then differ-
entiates into Tumor-Associated-Fibroblasts (TAFs) in tumor
stroma. As the only known mammalian coSMAD, SMAD4
transferred signaling from cytoplasm to TGFB signal. AR,
the symbol of androgen receptor, mainly functioned as a
DNA-binding transcription factor that regulates target gene
expression from cytoplasm into nucleus.
Loss of cell adhesions or polarity is widely associated
with CDH1 (E-cadherin). This process, referred to as EMT,
enhances motility and invasiveness of many cell types and
is often considered as a prerequisite for tumor infiltration
and migration. TGF𝛽mediated induction of EMT processes
is associated with specific stages of morphogenesis and
during tumorigenesis by activating downstream signaling
pathways in both Smad-dependent and Smad-independent
mechanisms. The upregulation of OCIAD2 expression by
TGF𝛽 stimulation, and downregulated OCIAD2 expres-
sion in metastatic prostate tissues, revealed that OCIAD2
played roles in TGF𝛽 promoted tumor cell migration, inva-
sion, and mobility. The discovery that OCIAD2 has been
enrolled in TGF𝛽 signal across CDH1 powerfully testified our
postulation—OCIAD2 could act as a downstream effector
of TGF𝛽 signals. In our predicted path, SMAD4 had the
largest expression value as well as the highest negative corre-
lation −0.696476 with differential expressed OCIAD2 among
SMADs families. Previous study reported that Smad3/4 coop-
erated with Snail1 which acted as corepressors of CDH1 in the
EMT process [21]. Due to the lack of information on protein
interaction with OCIAD2, future biological assay needs to
investigate the potential relationships between CDH1 and
OCIAD2 in tumor EMT. In addition, smad signaling is
required to maintain epigenetic silencing of some key EMT
related proteins in breast cancer progression [22]. Because
OCIAD2 frequently methylated in some kinds of cancers
[5, 6, 23], we speculate that activated TGF𝛽-Smad signaling
provides an epigenetic memory to maintain silencing of
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OCIAD2 in EMT as well. Thus, disruption of TGF𝛽-Smad4-
OCIAD2 signaling may be a useful therapeutic strategy to
target tumor progression.
Specifically, the predicted path TGFB1- TGFBR1-
SMAD2/3-SMAD4 was verified by [24, 25], and TGFB1’s
influence on AR with SMAD3 was also proved in [26].
4. Conclusions
In this study, a bioinformatics approach was developed, and
it demonstrated that the function-unknown protein ovarian
carcinoma immunoreactive antigen-like protein 2 (OCIAD2)
is probably regulated by TGF𝛽 and AR signals in the tumor
EMT process. OCIAD2 is an immunoreactive antigen, which
functions, involved pathways, and molecular mechanisms
have never been reported. Current popular signaling analysis
tools like IPA [12] are focusing on the highest differentially
expressed genes with sufficient literature supported, ignoring
signatures such as OCIAD2. Moreover, as the comprehensive
analysis of wide-field database, the output pathways of those
tools can hardly be specific for an interesting stimulation or
disease. Overcoming the insufficiency of the knowledge on
the new gene OCIAD2 and studying the modular signaling
mechanism from the given ligand to the pointed signature,
the pbMOO approach successfully answered the question
“how did the observed signature gene OCIAD2 get involved
in ligandTGF𝛽 stimulation signal,” anddetailed the predicted
pathways into the tumor microenvironment.
With pbMOO approach, a new pathway “TGF𝛽1-
TGF𝛽R1- AR-OCIAD2” in liver cancer mesenchymal stem
cell was predicted, which will differentiate into Tumor-
Associated-Fibroblasts (TAFs), one of the major components
of tumor stroma. Stromal-epithelial crosstalk regulates all
phases of cancer metastasis. In prostate cancer, androgen
signaling is central to stromal-epithelial cross-talk in tumor
progression. Tissue-based studies of human prostate cancer
have shown that stromal AR expression and transcriptional
activity downstream of the AR are lower in stromal cells
which are derived from carcinomas. Androgen Receptor
(AR) may promote hepatocarcinogenesis or suppress HCC
metastasis. These opposite roles of AR also occur in prostate
cancer [27]. The potential mechanisms for the AR dual roles
are possibly caused by the differential AR signals in different
cellular types having an oncogenic role in stroma and epithe-
lial cells, but a suppressive role in basal intermediate epithelial
cells. As DU-145 is an AR-independent cell lacking AR
protein expression, the predicted path from AR to OCIAD2
in prostate cancer needs more support of more biological
experiments. Further biological experiments are still needed
to explore the existence of pathway TGF𝛽-Smad4-OCIAD2
signaling in AR-dependent cell models as well.
The signal from TGF𝛽, via the AR, played a critical role
in the deregulation of TGF𝛽 signaling in prostate and/or liver
tumorigenesis, and those TGF𝛽 effectors (Smads 3 and 4)
serving as negative regulators of AR-mediated transcription
in cancer cells have been established by several investiga-
tions [28]. With pbMOO approach, the functional unknown
protein OCIAD2 was also enrolled into a signal pathway
“TGF𝛽1- TGF𝛽R1- SMAD2/3- SMAD4- AR-OCIAD2” in
tumor and adjacent microenvironment. Currently, clini-
cal studies using antiandrogens had disappointing results,
few beneficial effects on patients, or even less survivals.
Understanding the molecular mechanisms of AR in tumor
microenvironment will undoubtedly further improve the
results obtained with antitumor therapeutic strategies.
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